monoclonal antibodies

The findings reported in the journal Immunity support the development of a monoclonal antibody for prevention and treatment of influenza B — and will help guide efforts to develop a universal influenza vaccine.

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.

Vanderbilt's Scott Smith, MD, PhD, has been awarded a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to study the human immune response to tick bites and its role in preventing tick-borne illnesses.

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.